PharmaTelevision - Roche, Dan Zabrowski talks about changes in the industry as Roche celebrates 10 years of Roche Pharma Partnering

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Roche, Dan Zabrowski talks about changes in the industry as Roche celebrates 10 years of Roche Pharma Partnering

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dan Zabrowski, Head of Partnering at Roche.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Acquisition deal of Marcadia

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington DC. On this show I have Daniel Zabrowski, who is Global Head of Roche Partnering, welcome to the show.

Daniel Zabrowski:

Thank you very much for having me.

Fintan Walton:

It's good to have you again Dan on this show. As you know the world changes even in a year things have continued to move for the pharmaceutical industry as well as the biotech industry, how much have things changed from Roche's point of view in terms of the number of deals that you are doing, the types of pursuits that you are engaged in right now?

Daniel Zabrowski:

Well actually I think a lot of this could be traced back to the 2008 financial collapse where you know at that point there were two things that we saw from the pharma side of business development, number one was that there was a significant less there was a significant less available funding for the existing biotech companies which resulted in a decrease of the biotech community, and secondly there was I think a less of an appetite for venture capital that continued to invest in early technology, and so for us at Roche we've had to become even more creative in our financial deal structures, we are finding deals such as options deals or deals where the biotech investors are taking on more risk or becoming more prominent as well as earlier acquisitions so that the venture capitalist can get an exit and a good example of that was our acquisition of Marcadia last year where we started that particular discussion around our licensing opportunity and that turned into the acquisition of Marcadia.

Fintan Walton:

And when you make that decision what's the driver for that, I mean you could still obviously just done a licensing deal, so what was the thing that triggered the actual acquisition itself?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Daniel Zabrowski

Head

Daniel Zabrowski Ph.D. serves as Head of Roche Partnering at Chugai Pharmaceutical Co. Ltd. Mr. Daniel Zabrowski has been Head of Roche Partnering at Roche Holding AG since January 1, 2010. Mr. Zabrowski has been Global Head of Roche Pharma Partnering at Hoffmann-La Roche Inc. Since July 1, 2007. Mr. Zabrowski served as Head of Pharma Partnering at Roche Holding AG. He served as Head, Global Regulatory Affairs at Roche. He joined Roche in 1995 following the acquisition of Syntex, Inc., where he held a variety of positions in Regulatory Affairs. Before Syntex, Mr. Daniel Zabrowski led Regulatory Affairs in North America for Fujisawa Pharmaceutical Company. He serves as a Director of Chugai Pharmaceutical Co. Ltd. He began his career as a Researcher at G.D. Searle Pharmaceuticals. Mr. Zabrowski received Ph D in Organic Chemistry from Indiana University in 1987.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Roche

Roche, Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche. Roche has a majority stake in Chugai Pharmaceutical, Japan.